LUT014 gel significantly reduces acne-like rashes from anti-EGFR therapies in colorectal cancer patients, improving quality of life. The phase 2 trial showed 70% improvement with high-dose gel, ...

A breast lump is the most common and recognized symptom of breast cancer, according to a 2023 study published in Preventive Medicine Reports. Yet the research points out that awareness of other breast ...

A research team from the UCLA Health Jonsson Comprehensive Cancer Center, the University of Texas MD Anderson Cancer Center, and collaborators have demonstrated that a novel topical BRAF inhibitor gel ...

Researchers from the UCLA Health Jonsson Comprehensive Cancer Center and The University of Texas MD Anderson Cancer Center have demonstrated that a novel topical BRAF inhibitor gel called LUT014 ...

Please provide your email address to receive an email when new articles are posted on . ATR-04 has received a fast track designation from the FDA for epidermal growth factor receptor ...

Because of the now ubiquitous use of immunotherapies in cancer treatment, community dermatologists have an increasingly important role in identifying and often managing chronic adverse events (AEs) ...

Researchers from the UCLA Health Jonsson Comprehensive Cancer Center and The University of Texas MD Anderson Cancer Center have demonstrated that a novel topical BRAF inhibitor gel called LUT014 ...

Novel treatment allowed patients with colorectal cancer to successfully continue taking their cancer treatment with improved quality of life Acne-like skin rash is a common side effect from colorectal ...